Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

ne reduced negative symptoms after one year of treatment, but the difference between the two was not statistically significant.(1)

Additionally, a preliminary pooled analysis of the combined data for these two identically designed studies showed a statistically significant treatment effect in favor of asenapine after one year of treatment.

These large Phase III studies were conducted following a previous Phase II study where favorable data on negative symptoms were observed for asenapine.

About the study

This study was a 26-week extension of a randomized, double-blind, multicentered, multinational 26-week clinical trial evaluating the efficacy and safety of SAPHRIS compared to olanzapine in the treatment of patients with stable predominant, persistent negative symptoms of schizophrenia. Patients were initially randomized in the core study to SAPHRIS 5 to 10 mg twice daily or olanzapine 5 to 20 mg once daily for 26 weeks. In the core study, both SAPHRIS and olanzapine reduced negative symptoms over the 26-week treatment period, but the difference between the two was not statistically significant. Patients who continued after six months were maintained on the same double-blind treatment regimen for the 26-week extension study. In the extension study, SAPHRIS demonstrated statistically significantly greater change in NSA-16 total score from the core study baseline after one year of treatment, the primary prespecified endpoint of the extension study. A total of 468 patients were randomized in the core study, 195 of whom entered the extension study, with 146 completing a total of one year of treatment.

In the study, the most common adverse events reported for the SAPHRIS group (greater than 5 percent) during the one year treatment period were: insomnia, somnolence, weight increase, anxiety, headache, weight decrease, akathisia, diarrhea, dizziness, fatigue, nasopharyngit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... is pleased to announce that its three Promissory Note ... who advanced $ 100,000 each in July 2014 for ... Notes and related Coupons converted into 3,500,001 restricted common ... 5% coupon. Both the Note and the coupon were ...
(Date:9/29/2014)... , September 29, 2014 ... research report "Epigenetics Market by Product (Modifying Enzymes, ... Kit, Bisulphite Conversion Kit, Reagents), by Research ... - Global Forecast to 2019", published by ... major drivers, restraints, opportunities, current market trends, ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... and The Channel Group ("TCG"), a leader in ... advisors, have formed an alliance to expand the ... prospective clients. With the alliance, Burnham Securities will ... the scientific, clinical medicine and management in healthcare ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 312th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... Therapeutics,Inc. (Nasdaq: IMRX ), a biopharmaceutical company ... financial,results for the first quarter ended March 31, ... Highlights:, -- Entered into agreement with Abbott ... obligation under non-recourse promissory note issued in connection ...
... Spain, May 15 Forest,Laboratories, Inc. (NYSE: ... a webcast to discuss aclidinium bromide clinical and ... Annual Congress.,The webcast, which will include a slide ... May 21, 2008 at 9:30am New York time, ...
... Care Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends ... Industries, Inc. and,the International Expert Wound Care Advisory ... to Improve Pressure,Ulcer Prevention and Treatment: Implications of ...
Cached Biology Technology:ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 2ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 3ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 4ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 5ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 6ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 7Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:9/29/2014)... ago when the supercontinent of Pangea was starting to break ... different kinds of reptiles called phytosaurs and rauisuchids were at ... believed the two top predators didn,t interact much as the ... the land. But those ideas are changing, thanks largely to ... published online in September in the German journal ...
(Date:9/29/2014)... has significant anti-tumour activity in patients with advanced ... disease has progressed after chemotherapy, according to phase ... in Madrid, Spain. , "Reports of lung ... interest because these mutations may be associated with ... lead author Dr David Planchard, pulmonary oncologist at ...
(Date:9/29/2014)... 2014 NXT-ID, Inc. (Nasdaq: NXTD ... authentication company focused on the growing mobile commerce market, ... been named the Company,s Vice-President and Chief Financial Officer ... as Chief Financial Officer. Mr. Pereira will continue to ... a Director. Mr. Miceli, age 56, has ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3
... Chalmers University of Technology have built a very simple ... directions, even though the antenna is smaller than the ... online journal Nature Communications this week ... very low concentrations of gases or biomolecules. A ...
... 2011 The Translational Genomics Research Institute (TGen) is ... $3.5 million grant from Susan G. Komen for the ... form of this cancer that disproportionately affects African-Americans. ... of physicians and scientists called Promise Grants, multi-million dollar, ...
... of Utah researchers have discovered a new class of compounds ... and inhibit it from infecting cells an early step ... virus. Development and laboratory testing of the potential new ... a study set for online publication by Friday in the ...
Cached Biology News:Bimetallic nanoantenna separates colors of light 2TGen breast cancer research benefits from $3.5 million Komen award 2TGen breast cancer research benefits from $3.5 million Komen award 3Targeting HIV's sugar coating 2Targeting HIV's sugar coating 3
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
...
Biology Products: